BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock

Boston Scientific (BSX) has experienced substantial de-rating in 2026, trading down nearly 50% year-to-date as of June. Despite this sharp decline, BTIG maintains a bullish stance, suggesting the market may have overshot downside risk and created a valuation inflection point for recovery.

The forward P/E multiple of 14.45x positions BSX among the lowest in the S&P 500, indicating significant valuation compression. This metric suggests the market has priced in material headwinds—likely operational challenges, competitive pressures, or near-term revenue growth concerns in the medical device sector. The analyst's bullish rating against this backdrop implies conviction that current pricing fails to reflect normalized earnings recovery.

The cited 59.60% upside potential represents BTIG's price target relative to current levels, translating to a substantial mean-reversion thesis. This signals the analyst believes BSX has cleared worst-case scenarios and positioning becomes asymmetric for long-dated investors. Such divergence between analyst conviction and stock performance typically reflects either delayed market recognition or forthcoming catalysts.

Sector implication: Health Care valuations remain pressured amid margin concerns and regulatory uncertainty, but selective opportunities exist where quality franchises trade at distressed multiples. BTIG's bullish call on BSX may signal institutional conviction in cyclical recovery within medical devices, particularly if procedure volumes stabilize or cost structures improve.